I'm concerned about the bean counters at Biogen realizing that Tysabri as a Monotherapy application is going work against their best interest in terms of profit. They won't lie down I don't think and help the FDA determine this, if, in fact, this is the case.
I see a power struggle developing between Elan and Biogen relative to what and how the data should be interpreted down the road. Biogen doesn't necessarily want to see Tysabri OK'd for monotherapy right now. They would drag their feet a bit if they thought this was going to be the case to milk Avonex as long as possible. Elan really needs to get involved and stay on top of the data and what is really happening.
I'm concerned that KM may not have the sack to stay in there and fight for the truth. I think he may let Biogen dictate the way this recall is going to proceed. We need a strong board to make sure this will not be the case.
In a nut shell, I do not trust Biogen. And I believe the executives, through the way they traded on the data (some of them), reflect a greedy culture at that company. I think they have the potential to act like snakes. And I'm not sure if KM needs a wake up call regarding their deep seated motives or not.
Splint, you are absolutely mistaken about KM. When it all shakes out, if it ever becomes public knowledge, I think you will find that KM made an incredibly gutsy move and he did it to protect the patients.
No matter now. The Witches of Elan are plotting the demise of BiogenIdec as we speak ;-)
Biogen realizing that Tysabri as a Monotherapy application may not work against profit.
The deal between BIIB and ELN may not be "off" or depend on dual use therapy, that assumption is not easy to validate because partnering may include either or scenarios where both profit from the viability of the medication regardless of how administered
We need a wake up call: WHAT is the DEAL? Is it both foot the bill for R and D and share the profits regardless of mono or duality of dosage?